Edison Oncology Announces Treatment of First Patient in Orotecan® (irinotecan HCI oral solution) Phase I/IIa Clinical Trial for Patients with Recurrent Pediatric Solid Tumors
MENLO PARK, Calif., Feb. 17, 2022 /PRNewswire/ -- Edison Oncology Holding Corp. ("Edison Oncology"), a company established to develop and commercialize novel therapies targeting the fight against cancer today announced, that the first patient has received treatment with Orotecan ® (irinotecan HCI oral solution) in a Phase I/IIa clinical trial for patients with recurrent pediatric solid tumors.
The clinical trial will enroll up to 20 patients with recurrent pediatric and solid tumors, including but not limited to neuroblastoma, rhabdomyosarcoma, Ewing sarcoma, hepatoblastoma and medulloblastoma. The trial endpoints will characterize the pharmacokinetics of Orotecan vs. unformulated irinotecan in an already established oral treatment regimen, document safety and tolerability, and assess tumor response. The trial is currently enrolling patients at Duke University Children's Hospital and Cincinnati Children's Hospital Medical Center, with opening of additional sites anticipated in the near future.
"We are excited to have treated the first patient treated with Orotecan, our novel oral formulation of irinotecan, which we believe has the potential to improve the quality of life for pediatric and adult cancer patients, improve patient compliance and reduce costs" said Jeffrey Bacha, Edison Oncology's chief executive officer.
Further details of the trial can be found on clinicaltrials.gov (NCT04337177).
About Orotecan
Orotecan is a patented, novel formulation of irinotecan that was developed to improve palatability and clinical utility of an established oral delivery regimen for numerous pediatric cancers.
About Edison Oncology
Edison Oncology was founded in 2018 by experienced life science industry veterans to develop and commercialize novel therapies targeting the fight against cancer. Edison Oncology leverages a deep understanding of cancer biology and cancer pharmacology in order to identify and advance underdeveloped drug candidates with the potential to overcome treatment resistance, improve survival outcomes and the quality of life for cancer patients. Further information can be found at www.edisononcology.com.
Company Contact:
Jeffrey Bacha
Chief Executive Officer info@eohc.com
Investor Relations Contact:
Amato & Partners, LLC
Investor Relations Counsel admin@amatoandpartners.com
SOURCE Edison Oncology Holding Corp.
Released February 17, 2022